Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1 Plasma cell 1 Other solid neoplasm 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 315 Bortezomib 166 Lenalidomide 132 pomalidomide 113 daratumumab 96 carfilzomib 69 Cyclophosphamide 44 Calcium Dobesilate 41 belantamab mafodotin 32 elotuzumab 31 fludarabine 27 ixazomib 24 isatuximab 21 Melphalan 21 venetoclax 18 selinexor 17 talquetamab 15 Prednisone 15 plerixafor 14 Panobinostat 14 Granulocyte Colony-Stimulating Factor 14 Injections 12 idecabtagene vicleucel 11 Zoledronic Acid 11 Thalidomide 11 Azacitidine 11 pembrolizumab 10 tocilizumab 9 nirogacestat 9 liposomal doxorubicin 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Safety × Plasma cell × Clear all

NCT02786511 2020-01-22

Longterm Follow-up of Subjects Treated With bb2121

Celgene

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡